Related Experiment Video
Updated: May 19, 2026

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
Letter: Alopecia areata during ustekinumab administration: Co-existence or an adverse reaction?
Abstract:
Alopecia areata (AA) is a tissue-specific, T-cell-mediated autoimmune disease characterized by non-scarring hair loss. Ustekinumab is a human immunoglobulin monoclonal antibody that binds with the p40-subunit of interleukin-12 (IL-12) and IL-23 and has been licensed for the treatment of moderate to severe plaque psoriasis. The exact pathogenesis of AA remains unclear. However, increased Th1 serum cytokine levels have been associated with this condition. Thus, IL-12 inhibitors (ustekinumab) would be expected to treat or at least to prevent hair loss. We report two cases of acute AA occurring while on ustekinumab administration.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...